Amar Krishnaswamy

Amar Krishnaswamy

Auto-generated profile, based on publicly available information

Amar Krishnaswamy

Department of Cardiovascular Medicine, Cleveland Clinic, OH

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 June 2014 in European Heart Journal
Verified
Journal Article
Closed access
PDF file
BJBrandon M. Jones
Brandon M. Jones
SKSamir R. Kapadia
Samir R. Kapadia
NSNicholas G. Smedira
Nicholas G. Smedira
MRMichael Robich
Michael Robich
ETE. Murat Tuzcu
E. Murat Tuzcu
AKAmar Krishnaswamy
Amar Krishnaswamy
Ventricular septal rupture (VSR) after acute myocardial infarction is increasingly rare in the percutaneous coronary intervention era but mortality remains high. Prompt diagnosis is key and definitive surgery, though challenging and associated with high mortality, remains the treatment of choice. Alternatively, delaying surgery in stable patients may provide better results. Prolonged medical management is usually futile, but includes afterload reduction and intra-aortic balloon pump placement. Using full mechanical support to delay surgery is an attractive option, but data on success is limited to case reports. Finally, percutaneous VSR closure may be used as a temporizing measure to reduce shunt, or for patients in the sub-acute to chronic period whose comorbidities preclude surgical repair.

1 May 2020 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
AKAmar Krishnaswamy
Amar Krishnaswamy
YSYasser Sammour
Yasser Sammour
AMAntonio Mangieri
Antonio Mangieri
AKAmer Kadri
Amer Kadri
AKAntonette Karrthik
Antonette Karrthik
Azeem LatibAzeem Latib
Azeem Latib

1 August 2017 in World Neurosurgery
Verified
Journal Article
Closed access
EBE. Emily Bennett
E. Emily Bennett
KWKevin M. Walsh
Kevin M. Walsh
NTNicolas R. Thompson
Nicolas R. Thompson
AKAjit A. Krishnaney
Ajit A. Krishnaney

1 November 2009 in American Heart Journal
Verified
Journal Article
Closed access
AKAmar Krishnaswamy
Amar Krishnaswamy
ALA. Michael Lincoff
A. Michael Lincoff
VMVenu Menon
Venu Menon

5 March 2024 in Circulation
Verified
Journal Article
Closed access
SKSamir R. Kapadia
Samir R. Kapadia
AKAmar Krishnaswamy
Amar Krishnaswamy
BWBrian Whisenant
Brian Whisenant
SPSrinivasa Potluri
Srinivasa Potluri
VIVijay Iyer
Vijay Iyer
MLMartin B. Leon
Martin B. Leon
BACKGROUND: Atrial fibrillation (AF) is common in patients undergoing transcatheter aortic valve replacement (TAVR) and is associated with increased risk of bleeding and stroke. While left atrial appendage occlusion (LAAO) is approved as an alternative to anticoagulants for stroke prevention in patients with AF, placement of these devices in patients with severe aortic stenosis, or when performed at the same time as TAVR, has not been extensively studied. METHODS: WATCH-TAVR (WATCHMAN for Patients with AF Undergoing TAVR) was a multicenter, randomized trial evaluating the safety and effectiveness of concomitant TAVR and LAAO with WATCHMAN in AF patients. Patients were randomized 1:1 to TAVR + LAAO or TAVR + medical therapy. WATCHMAN patients received anticoagulation for 45 days followed by dual antiplatelet therapy until 6 months. Anticoagulation was per treating physician preference for patients randomized to TAVR + medical therapy. The primary noninferiority end point was all-cause mortality, stroke, and major bleeding at 2 years between the 2 strategies. RESULTS: The study enrolled 349 patients (177 TAVR + LAAO and 172 TAVR + medical therapy) between December 2017 and November 2020 at 34 US centers. The mean age of patients was 81 years, and the mean scores for CHA 2 DS 2 -VASc and HAS-BLED (Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile INR, Elderly, Drugs/alcohol concomitantly) were 4.9 and 3.0, respectively. At baseline, 85.4% of patients were taking anticoagulants and 71.3% patients were on antiplatelet therapy. The cohorts were well-balanced for baseline characteristics. The incremental LAAO procedure time was 38 minutes, and the median contrast volume used for combined procedures was 119 mL versus 70 mL with TAVR alone. At the 24-month follow-up, 82.5% compared with 50.8% of patients were on any antiplatelet therapy, and 13.9% compared with 66.7% of patients were on any anticoagulation therapy in TAVR + LAAO compared with TAVR + medical therapy group, respectively. For the composite primary end point, TAVR + LAAO was noninferior to TAVR + medical therapy (22.7 versus 27.3 events per 100 patient-years for TAVR + LAAO and TAVR + medical therapy, respectively; hazard ratio, 0.86 [95% CI, 0.60–1.22]; P noninferiority <0.001). CONCLUSIONS: Concomitant WATCHMAN LAAO and TAVR is noninferior to TAVR with medical therapy in severe aortic stenosis patients with AF. The increased complexity and risks of the combined procedure should be considered when concomitant LAAO is viewed as an alternative to medical therapy for patients with AF undergoing TAVR. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03173534.

21 March 2022 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
AKAmar Krishnaswamy
Amar Krishnaswamy
TIToshiaki Isogai
Toshiaki Isogai
AAAnkit Agrawal
Ankit Agrawal
SSShashank Shekhar
Shashank Shekhar
RPRishi Puri
Rishi Puri
SKSamir R. Kapadia
Samir R. Kapadia